Medical/Pharmaceuticals
HKeybio Launches World's First NHP Hidradenitis Suppurativa Model with High Clinical Consistency to Tackle Global Drug R&D Bottleneck
BOSTON and SUZHOU, China, April 21, 2026 /PRNewswire/ -- HKeybio Tech., a global leader in non-human primate (NHP) experimental animal model research and development, today announced the official launch of theworld's first NHP Hidradenitis Suppurativa (HS) model, based on over ten years of resear...
2026-04-21 20:30
4876
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
* Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) * Findings emphasize clinical decision-making in long-term management of inflammatory bo...
2026-04-21 20:00
5718
Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety t...
2026-04-21 20:00
3298
From Molecular Design to Scalable Execution: The Combined Impact of AI and Flow Chemistry
SHANGHAI, April 21, 2026 /PRNewswire/ -- As drug discovery places greater emphasis on practical execution and scalable delivery, flow chemistry is playing an increasingly important role across modern synthesis workflows. At the latest Viva Biotech's series webinar, "AI x Flow Chemistry: From Benc...
2026-04-21 17:57
5715
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
HONG KONG, April 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatme...
2026-04-21 10:54
4924
Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile
– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23% – No Grade 3 or higher adverse events related to RZ-001 observed – Highlights clinical potential of RNA trans-splicing ribozyme platform technology SEOUL, South...
2026-04-21 10:10
3936
Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Adminis...
2026-04-21 10:00
5750
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data we...
2026-04-20 22:00
4711
Datasea Intelligent Technology Ltd. Completes Delivery of Three AI Multimodal Solution Projects with Aggregate Contract Value of Approximately USD 1.01 Million
Completed Projects Further Support the Company's Transition Toward High-Margin, Solution-Driven Revenue and Strengthen Customer Stickiness Across AI Multimodal Application Scenarios BEIJING, April 20, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Comp...
2026-04-20 21:15
7059
Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows
* The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure * The standalone booth features STAgora simulation and an interactive touchscreen experience * An enhanced CURECA model is presented, illustrating next-generation automated labora...
2026-04-20 21:00
4773
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
* With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner * Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions ...
2026-04-20 19:30
3210
Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myelom...
2026-04-20 18:45
3941
Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce itsparticipation in the AACR Annual Meeting 2026, taking place April 19–22, 2026 in San Diego, California. At the meeting, the ...
2026-04-20 16:17
4848
AlphaGen Therapeutics to Present Preclinical Studies of Two Next-Generation Alpha Therapies at AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- AlphaGen Therapeutics (AlphaGen), a biopharmaceutical company that focuses on developing next-generation targeted alpha radiotherapies, today announced that it will present preclinical data on two advanced radiopharmaceutical programs at the 2026 Annual Me...
2026-04-20 14:57
3761
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchange on April 17th, 2026, Beijing Time. Alamar (NASDAQ:ALMR) issued shares at a price of $17 per sha...
2026-04-20 10:36
8042
Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal
Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal SHANGHAI, April 20, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance" or the "Company") announces that CHEST, the official journal of the American College of Chest Physicians...
2026-04-20 09:00
5482
ACT Genomics Upgrades Clinically Recognized Genomic Test to 101-Gene Panel with 7-Day Turnaround
TAIPEI, April 20, 2026 /PRNewswire/ -- ACT Genomics today announced a significant upgrade to the ACTDrug® series, its next-generation sequencing (NGS) genomic profiling service. The updated panel now covers 101 clinically relevant genes and offers a seven-working-day turnaround time, designed to ...
2026-04-20 09:00
4162
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company pr...
2026-04-20 08:15
5884
Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round
NEW YORK, April 19, 2026 /PRNewswire/ -- Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic, one of...
2026-04-20 08:00
4869
Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
• The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure VALBY, Denmark, April 20, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lund...
2026-04-20 01:29
4343
Week's Top Stories
Most Reposted
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 295 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 284 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 282 media titles]
2026-10-15 12:59
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 272 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
27416
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
16923